Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate as steroid-sparing agent in idiopathic retroperitoneal fibrosis
2008-007353-12Phase 3Terminated
- Sponsor
- University of Parma
- Start
- Nov 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of methotrexate in Idiopathic retroperitoneal fibrosis (RPF) and obstructive uropathy, sponsored by University of Parma. Primary endpoint: Disease remission rate at end of treatment. Started Nov 2008; status: terminated.
02
Drugs
methotrexate
03
Conditions
Idiopathic retroperitoneal fibrosis (RPF)obstructive uropathy
Beyond the preview
Go deeper on 2008-007353-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007353-12.